Menu
Search
|

Menu

Close
X

Sol Gel Technologies Ltd SLGL.OQ (NASDAQ Stock Exchange Global Market)

6.58 USD
-- (--)
As of Oct 18
chart
Previous Close 6.58
Open --
Volume --
3m Avg Volume 5,032
Today’s High --
Today’s Low --
52 Week High 16.47
52 Week Low 6.00
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
-0
FY17
0
FY16
0
EPS (USD)
FY18
-0.684
FY17
-1.886
FY16
-0.733
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.83
Price to Book (MRQ)
vs sector
--
4.89
Price to Cash Flow (TTM)
vs sector
--
22.92
Total Debt to Equity (MRQ)
vs sector
--
17.18
LT Debt to Equity (MRQ)
vs sector
--
12.76
Return on Investment (TTM)
vs sector
--
14.27
Return on Equity (TTM)
vs sector
--
15.99

EXECUTIVE LEADERSHIP

Alon Seri-Levy
Chief Executive Officer, Co-Founder, Director, Since
Salary: --
Bonus: --
Gilad Mamlok
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Itzik Yosef
Vice President - Operations, Since 2016
Salary: --
Bonus: --
Ofra Levy-Hacham
Vice President - Quality and Regulatory Affairs, Since
Salary: --
Bonus: --
Karine Neimann
Vice President - Projects and Planning, Chief Chemist, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Weizmann Science Park, 7, Golda
NESS-ZIONA     7403650

Phone: +9728.9313433

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

SPONSORED STORIES